The FDA has approved an ovarian cancer drug developed by Waltham-based Tesaro that some analysts believe could surpass $2 billion in peak sales.
Shares of Tesaro (Nasdsaq: TSRO) were up 6 percent in after-hours trading as of 8 p.m. after the company announced the approval of niraparib, a once-daily pill that will be sold under the brand name Zejula.
The 430-employee company previously said that regulators would issue a decision in mid-2017. In addition to being early, the approval is broad. It…
The FDA has approved an ovarian cancer drug developed by Waltham-based Tesaro that some analysts believe could surpass $2 billion in peak sales.
Shares of Tesaro (Nasdsaq: TSRO) were up 6 percent in after-hours trading as of 8 p.m. after the company announced the approval of niraparib, a once-daily pill that will be sold under the brand name Zejula.
The 430-employee company previously said that regulators would issue a decision in mid-2017. In addition to being early, the approval is broad. It…